These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3083199)

  • 1. Sorbinil: a member of the novel class of spirohydantoin aldose reductase inhibitors.
    Sarges R; Peterson MJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):101-4. PubMed ID: 3083199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spiro hydantoin aldose reductase inhibitors.
    Sarges R; Schnur RC; Belletire JL; Peterson MJ
    J Med Chem; 1988 Jan; 31(1):230-43. PubMed ID: 3121857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E
    Diabetes; 1985 Jan; 34(1):15-21. PubMed ID: 3917257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased nerve polyol levels in experimental diabetes and their reversal by Sorbinil.
    Whiting PH; Ross IS
    Br J Exp Pathol; 1988 Oct; 69(5):697-702. PubMed ID: 3143396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
    Yeh LA; Rafford CE; Beyer TA; Hutson NJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):4-9. PubMed ID: 3083208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, absolute configuration, and conformation of the aldose reductase inhibitor sorbinil.
    Sarges R; Bordner J; Dominy BW; Peterson MJ; Whipple EB
    J Med Chem; 1985 Nov; 28(11):1716-20. PubMed ID: 3934383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
    Griffin BW; McNatt LG; Chandler ML; York BM
    Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y; Fujimori S; Okada K
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Varagiannis E
    Pharmacology; 1985; 31(2):88-96. PubMed ID: 3927328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aldose reductase and its inhibition on sugar cataract formation.
    Kador PF; Akagi Y; Kinoshita JH
    Metabolism; 1986 Apr; 35(4 Suppl 1):15-9. PubMed ID: 3083204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonosmotic diabetic cataracts.
    Malone JI; Lowitt S; Cook WR
    Pediatr Res; 1990 Mar; 27(3):293-6. PubMed ID: 2138728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in lenses of diabetic rats.
    Gonzalez AM; Sochor M; McLean P
    Diabetes; 1983 May; 32(5):482-5. PubMed ID: 6404681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of aldose reductase inhibitors by determination of IC50 with bovine and rat lens extracts.
    Müller P; Hockwin O; Ohrloff C
    Ophthalmic Res; 1985; 17(2):115-9. PubMed ID: 3920598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.